Conceptos actuales en cirugía histeroscópica: superando barreras y ampliando límites / Current concepts in hysteroscopic surgery: Overcoming barriers by extending limits

Dentro de la patología intracavitaria estructural, los miomas submucosos plantean una mayor dificultad de manejo frente a los pólipos. Dentro de los miomas submucosos los miomas tipo0 y1 son más fáciles de tratar, dado que su separación del miometrio subyacente es técnicamente más fácil. Así, las cirugías histeroscópicas más complicadas son actualmente las miomectomías de miomas submucosos tipo2.Se ha empezado a describir también el manejo histeroscópico de miomas tipo3 por histeroscopia.Con este artículo planteamos hacer una revisión de los puntos más relevantes para llevar a cabo un tratamiento adecuado de este tipo de miomas, revisando su diagnóstico, las técnicas quirúrgicas, la preparación de la paciente y la forma de evitar complicaciones quirúrgicas.(AU)

Within structural intracavitary pathology, submucosal myomas are more difficult to manage than polyps. Of the submucosal myomas, type0 and type1 are easier to treat because their separation from the underlying myometrium is technically easier. Therefore, the most complicated hysteroscopic surgeries are currently type2 submucosal myomectomies.We have also begun to describe the hysteroscopic management of type3 myomas.With this article we propose to make a review of the most relevant points for the correct treatment of this type of myoma, reviewing its diagnosis, surgical techniques, patient preparation, and how to avoid surgical complications.(AU)

Hysteroscopy in postmenopause: from diagnosis to the management of intrauterine pathologies.

With the increase in life expectancy, women now live up to one-third of their life in menopause. Postmenopausal bleeding (PMB) is a common gynecologic complaint encountered by the clinician. Endometrial cancer is present in about 10% of patients with PMB. Nevertheless, many other conditions such as endometrial or cervical polyps, genital atrophy, or non-gynecologic conditions may also be present. Hysteroscopy has replaced blind diagnostic procedures and is now considered the gold-standard technique for the diagnosis and management of intrauterine pathology. Gynecologists in clinical practice should be familiar with the use of hysteroscopy in the diagnosis and treatment of the menopausal patient presenting with gynecologic complaints. The aim of this article is to report the current evidence on the role of hysteroscopy in the evaluation and management of the postmenopausal patient with intrauterine pathology.

Office hysteroscopy: back to the future!

Hysteroscopy and anesthesia have come a long way in the last 150 years. While traditionally performed in the operating theater under general anesthesia, the alternative approach - so-called 'office' hysteroscopy - has gained popularity in recent years. Supporters of this modality cite the 'see and treat' capabilities, avoidance of anesthesia, more rapid turn-around time, and favorable economics as advantages. On the other hand, some question the success rate, capabilities, and patient comfort levels as potential drawbacks. In this article, we review the evidence behind all of these points as well as the requirements for setting up an office hysteroscopy service.

Updates in office hysteroscopy: a practical decalogue to perform a correct procedure.

Nowadays, hysteroscopy is the gold standard for the diagnosis and treatment of intrauterine pathologies as it represents a safe and minimally invasive procedure that allows the visualization of the entire uterine cavity. Numerous technological innovations have occurred over the past few years, contributing to the development and widespread use of this technique. In particular, the new small-diameter hysteroscopes are equipped with an operating channel in which different mechanical instruments can be inserted, and they allow not only to examine the cervical canal and uterine cavity but also to perform biopsies or treat benign diseases in a relatively short time without anesthesia and in an outpatient setting. In this scenario, the operator must be able to perform hysteroscopy in the correct way to make this procedure increasingly safe and painless for the patient. This review aims to describe the ten steps to perform a correct office hysteroscopy, starting from patient counseling to the therapy after the procedure.

Variability in gynecologic case volume of obstetrician-gynecologist residents graduating from 2009 to 2017.

BACKGROUND: Residency training in obstetrics-gynecology has changed significantly over time, with residents expected to master an increasing number of surgical procedures. Residency operative case logs are tracked by the Accreditation Council for Graduate Medical Education, which sets case minimums for all procedures. In 2018, the Accreditation Council for Graduate Medical Education created a combined minimally invasive hysterectomy category and now requires graduating residents to complete a minimum of 70 minimally invasive hysterectomies. OBJECTIVES: The objectiges of the study were to evaluate the range of operative gynecological experience across graduating obstetrician-gynecologist residents in the United States and to estimate the number of residents able to meet new Accreditation Council for Graduate Medical Education minimum hysterectomy cases. STUDY DESIGN: Accreditation Council for Graduate Medical Education surgical case logs of graduating obstetrician-gynecologist residents from 2009 to 2017 were analyzed for case volume trends. RESULTS: The average total number of gynecological cases per resident decreased from 438.2 to 431.5 (P < .0001). Minimally invasive hysterectomy averages increased from 43.6 to 69.3 (P < .0001), a trend driven principally by an increase in total laparoscopic hysterectomies. Mean case log decreases were noted in invasive cancer (70.7 to 54.3), incontinence and pelvic floor (85.6 to 56.7), and total abdominal hysterectomies (74.4 to 42.9); (P < .0001 for all). Mean increases were seen in total laparoscopic (118.8 to 146.3) and operative hysteroscopy (68.6 to 77.1) cases (P < .0001 for all). The ratio of the 90th percentile to the 10th percentile of resident case logs showed substantial variation in surgical volume for all procedures, although this ratio decreased over time. Graduates who logged 70 minimally invasive hysterectomy cases were estimated to fall at the 51st percentile in 2017; this was down from the 91st percentile in 2009. CONCLUSION: Nationwide, graduates of obstetrician-gynecologist residency experience significant variability in their surgical training. Based on our extrapolation of Accreditation Council for Graduate Medical Education data, approximately half of residency graduates fell below the 70 case minimally invasive hysterectomy minimum in 2017. Meeting the new Accreditation Council for Graduate Medical Education hysterectomy minimums may be challenging for a significant proportion of residency programs. Understanding the scope and variability of gynecology training is needed to continue to improve and address gaps in resident education.

Reproductive surgery: glimpses into the past and thoughts for the future (part 2).

This month's Views and Reviews continues with part two of the series regarding reproductive surgery. The roles of reproductive surgery in müllerian anomalies, tubal and pelvic disease, fertility preservation, and male reproductive surgery are included. Augmenting each contribution, authors have added images and videos to their reflections.

Hysteroscopy and why macroscopic uterine factors matter for fertility.

For humans, the uterus is their first home. Accurate evaluation and effective therapy are central to optimizing the conditions for implantation and sustained pregnancy. For macroscopic intracavitary disease, hysteroscopy remains the gold standard for diagnosis and treatment. We review the role of hysteroscopy before fertility therapies. We also address intracavitary pathologies and their relevance to procreative outcomes. Controversies in the literature are noted and clarified, and trends in the field of hysteroscopy are identified regarding how they will influence the future of reproductive care and women's health.

Effectiveness and appropriateness in the application of office hysteroscopy.

With the advances in miniature instruments, office hysteroscopy on conscious patients has been the standard to explore the intrauterine pathology, with the ability to perform some minor procedures concomitantly. Patients usually appreciate the efficient "see and treat" procedures with such minimal discomfort that exempt from the inconvenience of going into the operating room and the need for anesthesia. However, controversies exist in the appropriateness of its application in some clinical situations. Concerns include (1) the criteria for hysteroscopy applied in the vast number of patients suffering from abnormal uterine bleeding or subfertility, and (2) the frequency for repeated hysteroscopy on some kinds of patients, such as those of endometrial cancer with fertility-sparing treatment for monitoring the disease, or those of severe intrauterine adhesion who need adhesiolysis for subsequent conception, in whom the appropriate protocol of repeatedly applying hysteroscopy lacks consensus. This article reviews the literature to find the best available evidence on the effectiveness of office hysteroscopy in comparison with other clinical diagnostic tools, as well as the current opinions on such controversies in its application.

Update on the Essure System for Permanent Birth Control.

In 2002, the U.S. Food and Drug Administration approved the Essure system for permanent birth control. Implantation with this device offers a minimally invasive option for permanent female contraception that is placed during a brief office visit. Unlike laparoscopic tubal sterilization, the Essure procedure requires no hospitalization or general anesthesia, resulting in minimal recovery time. After a decade of stability in the report of adverse effects, the U.S. Food and Drug Administration noted a sharp increase in patient-reported adverse events, including chronic pelvic pain, irregular bleeding, allergic reactions, and autoimmune-like reactions. In response to this increase in complaints, the U.S. Food and Drug Administration issued updated guidelines for patient education and counseling. This article discusses those updates, as well as implications for nurses who provide health care to women seeking permanent contraception.

Prevention of intrauterine post-surgical adhesions in hysteroscopy. A systematic review.

OBJECTIVE: The purpose of the present review is to provide a survey of the various measures of preventing adhesions used in hysteroscopic surgery. STUDY DESIGN: A systematic computerized literature search was conducted to provide a survey of the various measures used in hysteroscopic surgery to prevent adhesions. Finally, 29 studies were included in the analysis, showing a wide variety of methods and agents advocated in international literature. They are explained in various sections, based on the IUA prevention approach adopted (surgical technique, early second-look hysteroscopy, barrier method, pharmacological therapy). RESULTS: The results of our review show that (i) use of surgical techniques which reduce the use of electrosurgery should be preferred whenever possible (Level of evidence: 4); (ii) an early second-look hysteroscopy would appear to be an effective preventive, as well as therapeutic, strategy regarding IUA but studies on the topic are too few for relevant evidence; (iii) barriers methods are the most widely used and, among these, gel barriers have been proven to have a significant clinical effect on IUA prevention, because of higher adhesiveness and prolonged residence time on the injured surface (Level of evidence: 1b); (iv) the role of hormonal and antibiotic therapy in the prevention of post-operative IUA is difficult to evaluate as it has been used in association with other prevention strategies in most studies included in our review. CONCLUSIONS: Robust and high quality randomized trials to assess the effectiveness of different anti-adhesion therapies are still needed before one or more of these strategies may be strongly recommended for improving clinical outcomes in women treated by operative hysteroscopy.

Randomized, controlled trial comparing the efficacy of intrauterine balloon and intrauterine contraceptive device in the prevention of adhesion reformation after hysteroscopic adhesiolysis.

OBJECTIVE: To compare the efficacy of heart-shaped intrauterine balloon and intrauterine contraceptive device (IUD) in the prevention of adhesion reformation after hysteroscopic adhesiolysis. DESIGN: Prospective, randomized, controlled trial. SETTING: University hospital. PATIENT(S): A total of 201 women with Asherman syndrome. INTERVENTION(S): Women were randomized to having either a heart-shaped intrauterine balloon or an IUD fitted after hysteroscopic adhesiolysis. The devices were removed after 7 days. A second-look hysteroscopy was carried out 1 to 2 months after the surgery. MAIN OUTCOME MEASURE(S): Incidence of adhesion reformation and reduction of adhesion score before and after surgery. RESULT(S): Initially 201 cases were recruited; 39 cases dropped out, resulting in 82 cases in the balloon group and 80 cases in IUD group. The age, menstrual characteristics, pregnancy history, and American Fertility Society score before surgery were comparable between the two groups. The median adhesion score reduction (balloon group, 7; IUD group, 7) and the adhesion reformation rate (balloon group, 30%; IUD group, 35%) were not significantly different between the two groups. CONCLUSION(S): The heart-shaped intrauterine balloon and IUD are of similar efficacy in the prevention of adhesion reformation after hysteroscopic adhesiolysis for Asherman syndrome. CLINICAL TRIAL REGISTRATION NUMBER: ISRCTN 69690272.

Intrauterine Morcellator Devices: The Icon of Hysteroscopic Future or Merely a Marketing Image? A Systematic Review Regarding Safety, Efficacy, Advantages, and Contraindications.

The aim of this study was to analyze all available evidence regarding the use of intrauterine morcellator (IUM), for treatment of the most prevalent intrauterine benign lesions, compared to both traditional resectoscopy and conventional outpatient operative hysteroscopy in terms of safety, efficacy, contraindications, perioperative complications, operating time, and estimated learning curve. We reported data regarding a total of 1185 patients. Concerning polypectomy and myomectomy procedures, IUM systems demonstrated a better outcome in terms of operative time and fluid deficit compared to standard surgical procedures. Complication rates in the inpatient setting were as follows: 0.02% for IUM using Truclear 8.0 (Smith & Nephew Endoscopy, Andover, Massachusetts) and 0.4% for resectoscopic hysteroscopy. No complications were described using Versapoint devices. Office polipectomy reported a total complication rate of 10.1% using Versapoint device (Ethicon Women's Health and Urology, Somerville, New Jersey) and 1.6% using Truclear 5.0 (Smith & Nephew Endoscopy). The reported recurrence rate after polypectomy was 9.8% using Versapoint device and 2.6% using Truclear 8.0. Finally, the reported intraoperative and postoperative complication rate of IUM related to removal of placental remnants using Truclear 8.0 and MyoSure (Hologic, Marlborough, Massachusetts) was 12.3%. The available evidence allows us to consider IUM devices as a safe, effective, and cost-effective tool for the removal of intrauterine lesions such as polyps, myomas (type 0 and type 1), and placental remnants. Evidence regarding Truclear 5.0 suggests that it may represent the best choice for office hysteroscopy. Further studies are needed to confirm the available evidence and to validate the long-term safety of IUM in procedures for which current data are not exhaustive (placental remnants removal).

Anticoncepción definitiva femenina mediante técnicas endoscópicas (enero de 2014) / Definitive female contraception using endoscopic techniques (January 2014)

No disponible

Histeroscopia en el tratamiento de los pólipos placentarios / Hysteroscopy in the treatment of placental polyps

El concepto de pólipo placentario hace referencia a la existencia de restos placentarios, deciduales o fetales retenidos a nivel intrauterino tras haber presentado un aborto, una interrupción del embarazo, un parto o una cesárea. Se estima que la aparición de tejido retenido se produce en alrededor de un 1% de los partos a término y probablemente tengan una incidencia mayor en los partos pretérmino y en abortos. Entre los síntomas clínicos de presentación destacan el sangrado genital, más abundante o prolongado de lo habitual, y el dolor abdominal acompañado o no de fiebre, debido a que los restos retenidos tienen predisposición a infectarse por la flora cérvico vaginal. El diagnóstico de esta afección se basa en la historia clínica y la exploración ginecológica, los hallazgos ecográficos y la confirmación de restos placentarios en el estudio anatomopatológico una vez evacuada la cavidad. Entre las distintas opciones de tratamiento, la más utilizada continúa siendo el legrado uterino, otras opciones incluyen el tratamiento médico con misoprostol por vía oral o vaginal, la resección ecoguiada del tejido trofoblástico, la extracción con control histeroscópico y la evacuación de restos con resectoscopio bajo visión directa. Presentamos una serie de 7 casos de persistencia de restos uterinos tras un aborto en los que se utilizó el resectoscopio como método de evacuación bajo visión directa de dichos restos, realizando igualmente una revisión bibliográfica de la técnica(AU)

Placental polyp is a polypoid mass due to retention of decidual or fetal placental tissue in the uterine cavity after miscarriage or parturition. The estimated incidence of retained placental tissue is approximately 1% after term delivery and is probably higher after miscarriage and preterm delivery. Clinical symptoms include heavier and longer than usual uterine bleeding and pelvic pain with or without fever, since retained products are prone to infection from the cervicovaginal flora. Diagnosis is based on clinical history and gynecological examination, ultrasound findings and confirmation of trophoblastic tissue after evacuation of the uterine cavity. The most widely used treatment option continues to be dilatation and curettage. Other options include medical treatment with oral or vaginal misoprostol, ultrasound-guided resection of retained products, hysteroscopy-controlled evacuation, and resection using a rectoscope under direct vision. We present a case series of seven patients with retained products of conception after miscarriage. The method chosen to remove these products was evacuation using a rectoscope under direct vision of the cavity. We also provide a literature review of this entity(AU)

Cirugía histeroscópica del istmocele: ¿solución a un viejo problema? / Hysteroscopic surgery of isthmocele: a solution to an old problem?

El aumento de cesáreas en los últimos años en los países desarrollados conlleva asociado la posibilidad de aparición de una serie de problemas derivados de ellas; entre ellos, los más conocidos son los obstétricos, siendo los ginecológicos menos frecuentes. Entre estos últimos destaca el istmocele o defecto de cicatrización a nivel de la incisión de una cesárea previa. Este consiste en una saculación a nivel ístmico que se asocia a sangrado posmenstrual, dolor abdominal y esterilidad secundaria. Presentamos una revisión del tema con los datos disponibles hasta el momento actual(AU)

The increase in cesarean sections in developed countries in recent years has led to the possibility of a parallel increase in the problems associated with this procedure. The best known are obstetric problems, while gynecological complications are less frequent. A cesarean scar defect can sometimes be found at the incision of a previous cesarean section, consisting of a sacculation of isthmic localization where residual menstrual blood accumulates, causing post-menstrual bleeding, abdominal pain and secondary infertility. We present a review of the topic with the evidence available to date(AU)

Tratamiento conservador del acretismo placentario / Conservative management of placenta accreta

Introducción. El acretismo placentario ha aumentado debido al incremento de la cirugía uterina previa (en particular las cesáreas). La conducta ha evolucionado de un abordaje quirúrgico radical a un tratamiento conservador. Caso clínico. Gestante de 26,1 semanas que ingresó por rotura prematura de membranas. A los 3 días se realizó una cesárea por riesgo de pérdida de bienestar fetal apreciando acretismo placentario, dejando un fragmento en el lecho cornual. Dada la ausencia de sangrado se decidió adoptar una conducta expectante. El control clínico posterior fue correcto. Los seguimientos ecográfico e histeroscópico observaron una reducción progresiva del tamaño placentario desapareciendo a los 5 meses posparto. Discusión. El manejo óptimo de la placenta acreta sigue siendo discutido en la literatura médica. En casos seleccionados, deberíamos ofrecer la posibilidad de realizar un tratamiento conservador, reduciendo la morbilidad y preservando la fertilidad de la paciente (AU)

Introduction. Placental accreta has increased because of the greater use of prior uterine surgery, especially cesarean section. Treatment has evolved from a radical surgical approach to conservative management. Case report. A woman at 26.1 weeks of pregnancy was admitted to hospital because of premature rupture of membranes. Three days after a cesarian section was performed for suspected fetal distress, we observed placenta accreta. A fragment of placenta was left in the cornual bed. Given the absence of bleeding, an expectant attitude was adopted. Subsequent follow-up showed no abnormalities. Ultrasound and hysteroscopic monitoring showed a progressive reduction of placental size until its disappearance at 5 months postpartum. Discussion. The optimal management of placenta accreta remains controversial in the literature. In selected cases, we should offer the possibility of conservative treatment, reducing morbidity and preserving the fertility of the patient (AU)